Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 patients in randomized Phase 2b/3 clinical trial
- Written by Media Outreach
- French regulator, ANSM, as well as Ethics Committee, CPP, have cleared ABX464 for Phase 2b/3 "miR-AGE" testing
- The anti-inflammatory mechanism of action could prevent and treat cytokine storm and hyper-inflammation, which lead to acute respiratory distress syndrome (ARDS) and death of COVID-19 patients
- New data[1] show ABX464 inhibits SARS-CoV-2...
